<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01176578</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00047188</org_study_id>
    <nct_id>NCT01176578</nct_id>
  </id_info>
  <brief_title>Exercise Endothelial Progenitor Cells (EPCs) and Type 2 Diabetes</brief_title>
  <acronym>EPC-DM</acronym>
  <official_title>Effects of Exercise on the Regulation of EPCs in Obesity, Insulin Resistance, and Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baltimore VA Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baltimore VA Medical Center</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The discovery of the role of endothelial progenitor cells (EPCs) and their involvement in
      the cardiovascular complications of type 2 diabetes (T2DM) would quickly have a significant
      impact on the millions of Americans who have T2DM. This project is designed to 1) determine
      the mechanisms underlying EPC dysfunction in older, sedentary adults with T2DM compared
      those with normal glucose metabolism and impaired glucose metabolism, and 2) determine if
      aerobic exercise training is an efficacious therapy for EPC dysfunction in T2DM, and whether
      improvement in EPC number and function translates to improved endothelial function,
      increased capillarization, and improved glucose metabolism in T2DM.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2011</start_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Non-Randomized, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Prevention</study_design>
  <primary_outcome>
    <measure>Endothelial progenitor cell number</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Endothelial progenitor cell number</measure>
    <time_frame>6-month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Skeletal muscle capillarization</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Skeletal muscle capillarization</measure>
    <time_frame>6-month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiorespiratory Fitness</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiorespiratory Fitness</measure>
    <time_frame>6-month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>T2DM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Type 2 Diabetes Mellitus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IGT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Impaired Glucose Tolerance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NGT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal Glucose Tolerance</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aerobic Exercise Training</intervention_name>
    <description>6 months of aerobic exercise training, 3 days per week</description>
    <arm_group_label>T2DM</arm_group_label>
    <arm_group_label>IGT</arm_group_label>
    <arm_group_label>NGT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 50-80

          -  Non-smoker

          -  If woman, postmenopausal &gt;1 year

        Exclusion Criteria:

          -  History of heart disease or stroke

          -  Cancer

          -  Poorly controlled hypertension or dyslipidemia

          -  Kidney or Liver diseases
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sarah Horlitz, MS</last_name>
    <phone>410-605-7000</phone>
    <phone_ext>4823</phone_ext>
    <email>sarah.horlitz@va.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baltimore VA Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Horlitz, MS</last_name>
      <phone>410-605-7000</phone>
      <phone_ext>4823</phone_ext>
      <email>sarah.horlitz@va.gov</email>
    </contact>
    <investigator>
      <last_name>Steven J Prior, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <lastchanged_date>July 21, 2011</lastchanged_date>
  <firstreceived_date>August 5, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Steven J. Prior, Ph.D.</name_title>
    <organization>University of Maryland School of Medicine</organization>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
</clinical_study>
